|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **A. General Information** | |  |  | | | |  | | | | |  | | |  | | |  | | |  | | |
| ***Project Title & Project #:*** | | ***ABCD’s of Reducing Stroke*** | | | | | | | | | | | | | | | | | | | | | |
| ***Department/Division/Team:*** | | ***ACTION Network*** | | | | | | | | | | | | | | | | | | | | | |
| ***Population:*** | | Heart failure patients implanted with ventricular assist devices | | | | | | | | | | | | | | | | | | | | | |
| ***Brief Project Description (AIM):*** | | To decrease the percent of patients who have a stroke in the first 30 days of support by 33%. | | | | | | | | | | | | | | | | | | | | | |
| ***Measures:*** | | Percentage of all VAD patients, Berlin patients, paracorporeal CF device patients, and intracorporeal CF device patients who have a stroke. | | | | | | | | | | | | | | | | | | | | | |
| ***Prepared By:*** | | ACTION stroke leaders + Paige Krack | | | | | | | | | | | | | | | | | | | | | |
| ***Date:*** | | March 15, 2021 | | | | | | | | | | | | | | | | | | | | | |
| **B. Project Background:** | |  |  | | | |  | | | | |  | | |  | | |  | | |  | | |
| ACTION has been working to reduce the frequency of stroke associated with pediatric VAD care ever since it was established in 2017. Previous studies showed stroke rates in children on VADs ranged from 10% to 29% depending on device. We introduced the **ABC**’s of Stroke Prevention to standardize care and ultimately improve outcomes. **These ABCs have dramatically decreased the rate of stroke to <12% in Berlin Heart and <5% in implantable VADs.** The primary purpose of this project is to continue to test interventions to further drive down the stroke rate. | | | | | | | | | | | | | | | | | | | | | | | |
| **C. Project Scope (and exclusions)**: | | | | | | | | | | | | | | | | | | | | | | | |
| This project seeks to define additional strategies for reducing strokes. Interventions will be selected and tailored by type of device.  Initial strategies include a rigorous comparison to historical data to help refine stroke prevention protocols and data collection. Furthermore, the network has begun work on further optimizing anticoagulation practices.  Another intervention will be organized **D**iscussion & **D**ata sharing of all stroke events, which includes the creation and testing of stroke case presentation and discussion forums. This will be investigative work to better identify common categories for root causes of strokes and allow a deeper understanding of the details of each patient who had a stroke to find commonalities and trends.  Additional interventions will then be developed based on learnings from the Discussion & Data calls using the traditional Model for Improvement methodology. | | | | | | | | | | | | | | | | | | | | | | | |
| **D. High Level Timeline/Schedule:** | | | | |  |  | | | |  | | | |  | | |  | |  | | | |  |
| ***July 2020 – March 2021: Design Phase***   * Discuss next area of focus and review most current data * Create project charter and define scope of project * Align on communication: meeting frequency, learning method   ***April 2021***   * Align on SMART Aims * Plan M&M logistics for rolling out * Develop process measures for M&M intervention * Finalize working/operational definitions of M&M intervention * Create invitation packet   ***May 2021***   * Send out invitation packet and recruit teams for ABCD’s project   ***June - December 2021***   * Kick off project with participating teams * Communicate participation expectations and ask for commitment * Begin testing of M&Ms * Update Key Driver Diagram with learnings * Identify additional interventions to test based upon M&M findings | | | | | | | | | | | | | | | | | | | | | | | |
| **E. Communication & Expectations:** | | | | | |  | | | |  | | | |  | | |  | |  | | | |  |
| Primary methods of communication will be in the form of emails and regularly meetings hosted by ACTION. Teams who agree to participate in the project will be expected to attend monthly meetings, test interventions, and submit data regularly into Simplified Clinical and REDCap. | | | | | | | | | | | | | | | | | | | | | | | |
| **G. Project Risks & Mitigation**: | | | | | | | | | | | | | | | | | | | | | | | |
| **Risk** | **Level (high/med/low)** | | | | | | | **Mitigation and Escalation Strategy** | | | | | | | | | | | | | | | |
| Parent engagement |  | | | | | | |  | | | | | | | | | | | | | | | |
| Regular data submission |  | | | | | | |  | | | | | | | | | | | | | | | |
| Teams participating in M&Ms |  | | | | | | |  | | | | | | | | | | | | | | | |
| **F. Roles and Responsibilities** | | | |  | | | | |  | | | |  | | |  | | | |  | |  | | |
| **Sponsor/Champion:** Provides overall direction on the project. | | | | | | | | | | | | | | | | | | | | | | | | |
| **Name** | | | | | | | | | | | **Title/Role** | | | | | | | | | | | | | |
| Angie Lorts | | | | | | | | | | |  | | | | | | | | | | | | | |
| David Rosenthal | | | | | | | | | | |  | | | | | | | | | | | | | |
| **Team Leader:** Leads the team and provides guidance on scope of the project. | | | | | | | | | | | | | | | | | | | | | | | | |
| **Name** | | | | | | | | | | | **Title/Role** | | | | | | | | | | | | | |
| Chet Villa | | | | | | | | | | |  | | | | | | | | | | | | | |
| Christina VanderPluym | | | | | | | | | | |  | | | | | | | | | | | | | |
| Rob Gajarski | | | | | | | | | | |  | | | | | | | | | | | | | |
| Jenna Murray | | | | | | | | | | |  | | | | | | | | | | | | | |
| Mary Mehegan | | | | | | | | | | |  | | | | | | | | | | | | | |
| **Project Support** (**QIC/QOM/Data Analytics/Project Manager Support):** Leads in the planning & development of the project; manages the project to scope and/or provides data analysis and reporting expertise for the project. | | | | | | | | | | | | | | | | | | | | | | | | |
| **Name** | | | | | | | | | | | **Title/Role** | | | | | | | | | | | | | |
| Lauren Smyth | | | | | | | | | | | Program Manager | | | | | | | | | | | | | |
| Paige Krack | | | | | | | | | | | Quality Improvement Specialist | | | | | | | | | | | | | |
| Chloe Connelly | | | | | | | | | | | Data Analyst | | | | | | | | | | | | | |
|  | | | | | | | | | | |  | | | | | | | | | | | | | |
|  | | | | | | | | | | |  | | | | | | | | | | | | | |
| **Team Members:** Works toward the deliverables of the project. | | | | | | | | | | | | | | | | | | | | | | | | |
| **Name** | | | | | | | | | | | **Title/Role** | | | | | | | | | | | | | |
|  | | | | | | | | | | |  | | | | | | | | | | | | | |
|  | | | | | | | | | | |  | | | | | | | | | | | | | |
|  | | | | | | | | | | |  | | | | | | | | | | | | | |
|  | | | | | | | | | | |  | | | | | | | | | | | | | |
|  | | | | | | | | | | |  | | | | | | | | | | | | | |
| **Family/Patient Representative:** | | | | | | | | | | | | | | | | | | | | | | | | |
| **Name** | | | | | | | | | | | **Title/Role** | | | | | | | | | | | | | |
|  | | | | | | | | | | |  | | | | | | | | | | | | | |
|  | | | | | | | | | | |  | | | | | | | | | | | | | |
| **H. Signatures** | | | | | | | | | | | | | | | | | | | | | | | | |
| **Sponsor/Champion:** | | | | | | | | | | | | | | | | | | | | | | | | |
| **Name** | | | | | | | | | | | **Signature** | | | | | | | | | **Date** | | | | |
|  | | | | | | | | | | |  | | | | | | | | |  | | | | |
|  | | | | | | | | | | |  | | | | | | | | |  | | | | |
|  | | | | | | | | | | |  | | | | | | | | |  | | | | |
| **Team Leader:** | | | | | | | | | | | | | | | | | | | | | | | | |
| **Name** | | | | | | | | | | | **Signature** | | | | | | | | | **Date** | | | | |
|  | | | | | | | | | | |  | | | | | | | | |  | | | | |
|  | | | | | | | | | | |  | | | | | | | | |  | | | | |
|  | | | | | | | | | | |  | | | | | | | | |  | | | | |